Christopher Raymond
Stock Analyst at Piper Sandler
(2.49)
# 2,348
Out of 4,944 analysts
133
Total ratings
50.46%
Success rate
-1.81%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Neutral | $8 → $9 | $5.75 | +56.52% | 9 | Aug 6, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $69.89 | +0.16% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $135.19 | -14.93% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $0.66 | +1,262.40% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $58.30 | +116.12% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $1.81 | +120.99% | 3 | Feb 11, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $395.92 | +34.62% | 8 | Jan 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,195 → $1,013 | $561.55 | +80.39% | 7 | Jan 27, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $140 | $28.97 | +383.26% | 5 | Jan 13, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Overweight | $72 | $33.51 | +114.86% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $220 | $201.47 | +9.20% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $1.70 | +664.71% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $4.45 | +1,585.39% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $14.39 | +428.14% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $1.31 | +663.36% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $10.73 | +207.55% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $3.03 | +131.02% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $11.98 | +83.64% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $3.30 | +21.21% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $8.34 | +199.76% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $289.33 | -0.46% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $36.61 | +11.99% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $48.19 | -41.90% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $78.24 | -48.88% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $6.68 | +1,247.31% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.70 | +5,547.06% | 2 | Mar 13, 2020 |
Ardelyx
Aug 6, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $5.75
Upside: +56.52%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $69.89
Upside: +0.16%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $135.19
Upside: -14.93%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $0.66
Upside: +1,262.40%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $58.30
Upside: +116.12%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $1.81
Upside: +120.99%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $395.92
Upside: +34.62%
Regeneron Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $561.55
Upside: +80.39%
Ultragenyx Pharmaceutical
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $28.97
Upside: +383.26%
Monopar Therapeutics
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $33.51
Upside: +114.86%
Dec 17, 2024
Maintains: Overweight
Price Target: $212 → $220
Current: $201.47
Upside: +9.20%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $1.70
Upside: +664.71%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $4.45
Upside: +1,585.39%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $14.39
Upside: +428.14%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $1.31
Upside: +663.36%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $10.73
Upside: +207.55%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $3.03
Upside: +131.02%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $11.98
Upside: +83.64%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $3.30
Upside: +21.21%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $8.34
Upside: +199.76%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $289.33
Upside: -0.46%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $36.61
Upside: +11.99%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $48.19
Upside: -41.90%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $78.24
Upside: -48.88%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $6.68
Upside: +1,247.31%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.70
Upside: +5,547.06%